NCT06347198View on ClinicalTrials.gov

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

May 1, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib

Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;

DRUG

Sintilimab

Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;

DRUG

Inulin

Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.

Trial Locations (1)

430030

RECRUITING

Min Jin, Wuhan

All Listed Sponsors
collaborator

Huazhong University of Science and Technology

OTHER

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER